Global Initiative for Psychedelic Science Economics (GIPSE) Part of our Year in Review series Elliot Marseille DrPH, MPP, Stefano Bertozzi, MD, PhD, and James G. Kahn, MD, MPH are seeking to apply policy-relevant economic analyses to the pursuit of achieving the apparent potential of psychedelic therapies for mental health conditions. Their efforts in this realm are broadly housed within the…

Source

Previous articleNuminus Receives Clinical Trial Application Approval from Health Canada for Experiential Psychedelic-Assisted Therapy Training using Psilocybe Cubensis Tea
Next articlePharmaTher Holdings Announces FDA Grant of Orphan Drug Designation to KETARX™ (Ketamine) for the Treatment of Rett Syndrome